ICU Medical, Inc. — Q1 2015 Form 10-Q
Business context and period. Unaudited results for the three months ended March 31, 2015, compared with Q1 2014. ICU Medical develops, manufactures, and sells medical devices for infusion therapy, oncology, and critical care. The company reports one business segment. Amounts below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Total revenue | $81.5 | $73.2 |
| Gross profit / gross margin | $42.5 / 52% | $36.0 / 49% |
| Operating income | $11.0 | $9.9 |
| Net income | $9.7 | $6.7 |
| Diluted EPS | $0.60 | $0.43 |
| Operating cash flow | $13.3 | $12.7 |
- Revenue increased 11% as reported; management said constant-currency revenue would have been $83.9 million, up 15%.
- Infusion therapy sales rose 17% to $58.5 million; oncology sales were $8.9 million, down 1%; critical care sales were $13.7 million, down 2%. Management attributed much of the international weakness to the stronger U.S. dollar.
- Gross margin improved primarily on favorable customer and product mix and lower operating expenses. SG&A fell to $20.2 million from $22.5 million, while R&D increased to $4.3 million from $3.6 million.
- Net income benefited from a lower estimated effective tax rate: 16%, compared with 34% in Q1 2014. The company cited tax credits, deductions, and discrete benefits related to tax examinations and tax-reserve estimates.
Liquidity, cash flow, and capital resources
- Cash, cash equivalents, and investment securities totaled $354.8 million at March 31, 2015, up from $346.8 million at year-end. Cash and cash equivalents alone were $308.5 million.
- Operating cash flow was $13.3 million. Investing activities provided $20.0 million, primarily from net investment-security sales of $22.6 million, partly offset by $2.4 million of capital expenditures. Financing activities provided $7.4 million. Cash increased $32.7 million, including a $8.0 million adverse effect from exchange rates.
- The balance sheet reports no borrowings. Current liabilities were $32.9 million; stockholders’ equity was $518.1 million.
- Management estimated 2015 capital expenditures of $12 million to $14 million, primarily for manufacturing equipment and molds in the U.S. and Mexico and for IT. It said existing cash, investments, and expected operating cash flows should fund operations for at least the next 12 months.
- $24.6 million of cash and cash equivalents was held by foreign subsidiaries and was expected to remain permanently reinvested outside the U.S. The company disclosed $46.3 million of investment securities, all described as investment grade.
Material changes, unusual items, and risks
- Hospira arbitration: On April 2, 2015, an arbitrator awarded Hospira C$8.2 million (approximately $6.5 million) in a contract dispute and required ICU Medical to pay 75% of Hospira’s legal fees, estimated at C$0.8 million (approximately $0.6 million). ICU Medical recorded a $7.1 million Q1 legal-settlement accrual. Management said the ruling was not expected to significantly affect future earnings.
- Customer concentration: Hospira generated 36% of Q1 2015 revenue, compared with 35% in Q1 2014, and represented 25% of accounts receivable at March 31, 2015. The company’s distribution agreements with Hospira extend through most of 2018. Loss of or reduced demand from this customer could materially affect results.
- Currency exposure: Approximately 14% of Q1 revenue was denominated in euros. The company does not hedge its foreign-currency exposures; management estimated that a 10% euro exchange-rate change would affect specified net balance-sheet assets by approximately $8.5 million. Foreign currency translation produced a $10.1 million Q1 comprehensive loss.
- Other items: A $0.6 million restructuring accrual remained at March 31, 2015, related to the 2014 workforce reduction. The company had $22.5 million remaining under its share-purchase authorization. It reported no material change to previously disclosed risk factors and stated that disclosure controls were effective.
- Risks cited include dependence on major customers and distributors, foreign-exchange movements, competition and price pressure, product development and regulatory outcomes, manufacturing or supply disruptions, and healthcare-sector changes. Results may also fluctuate with seasonality and large-customer ordering patterns.
Important facts for investors to verify
- Review the Hospira arbitration award, the recorded $7.1 million accrual, and any subsequent settlement, payment, or effect on the customer relationship.
- Track Hospira’s share of revenue and receivables, contract terms through 2018, and the drivers of infusion-therapy growth.
- Assess whether revenue and margins remain strong after considering currency movements, customer/product mix, and the one-time legal charge.
- Monitor the sustainability of the unusually low 16% effective tax rate and any changes in discrete tax benefits or reserves.
- Compare actual capital spending with the $12 million to $14 million estimate and monitor cash generation, investment liquidity, and foreign-held funds.